

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, DC 20549

**Amendment No. 1
to
FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Calliditas Therapeutics AB

(Exact name of registrant as specified in its charter)

Sweden
(State or other jurisdiction of
Incorporation or organization)

Not applicable
(I.R.S. Employer
Identification No.)

Kungsbron 1, C8
Stockholm, Sweden
(Address of principal executive offices)

SE-111 22
(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of exchange on which each class is to be registered
American Depositary Shares, each representing two common shares, quota value SEK 0.04 per share	The Nasdaq Stock Market LLC
Common shares, quota value SEK 0.04 per share*	The Nasdaq Stock Market LLC*

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement file number to which the form relates:
333-238244

Securities to be registered pursuant to Section 12(g) of the Act:
None
(Title of class)

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent the right to receive common shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

INFORMATION REQUIRED IN REGISTRATION STATEMENT

The undersigned Registrant hereby amends the following Items or other portions of its Registration Statement on Form 8-A, dated June 2, 2020.

Item 1. Description of Registrant's Securities to be Registered.

Calliditas Therapeutics AB (the "Registrant") hereby incorporates by reference (a) the description of its common shares, quota value SEK 0.04 per share, contained under the heading "*Description of Share Capital and Articles of Association*", (b) the description of its American Depositary Shares, each representing two common shares, quota value SEK 0.04 per share, contained under the heading "*Description of American Depositary Shares*" and (c) the information set forth under the heading "*Material Income Tax Considerations*", in each case, in the Company's Registration Statement on Form F-1 ([333-238244](#)), as originally filed with the Securities and Exchange Commission on May 14, 2020, as amended from time to time (the "Registration Statement"). In addition, all of the above-referenced descriptions included in any prospectus forming a part of the Registration Statement subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933 shall be deemed to be incorporated by reference herein.

Item 2. Exhibits.

Under the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

CALLIDITAS THERAPEUTICS AB

Date: June 3, 2020

By: /s/ Renée Aguiar-Lucander
Renée Aguiar-Lucander
Chief Executive Officer
